Peptides are legal in the United States through three routes: as FDA-approved drugs such as semaglutide, approved 5 December 2017, tesamorelin, approved 10 November 2010, and teriparatide, approved 26 November 2002 [11, 12, 13]; as 503A compounded preparations when the bulk substance meets one of the three statutory conditions and a patient-specific prescription exists [1]; and as investigational drugs under an IND [5]. A peptide sold online with a research use only label for human use fits none of those routes, and the FDA has stated in a warning letter that such labeling does not change a product’s status as an unapproved new drug [9].
Each route carries its own paperwork, and the 503A category record moved several times between 2023 and November 2026. The sections below take the routes in turn, then FDA’s own documents on research use only labeling, the role of the state boards, and the documentation a practice keeps for each peptide it offers. ExaVeyra Sciences supplies licensed practices, and the prescribing decision in every case belongs to the practitioner.
Regulatory status
A peptide is legal to prescribe and dispense in the United States when it is an FDA-approved drug, when a 503A pharmacy compounds it from an eligible bulk substance against a patient-specific prescription, or when a sponsor supplies it for a clinical investigation under an IND [1, 5]. As of 4 November 2026, BPC-157, TB-500, CJC-1295, ipamorelin and injectable GHK-Cu sit in FDA’s table of withdrawn 503A nominations, GHK-Cu for non-injectable routes returned to category 1 on 14 May 2026, and a draft HHS interim policy of 30 October 2026 states that HHS does not intend to act against 503A compounding of six named peptides under ten conditions [2, 3, 8]. ExaVeyra offers non-catalog peptides for IND-authorized clinical trials through our pharmacy partner, with the sponsor’s IND number, sponsor details and protocol confirmed before any supply, and the practitioner decides any use.
Approved peptide drugs travel the same route as every other drug
The clearest legal route is an approved application. Semaglutide was approved under NDA 209637 on 5 December 2017 after a phase 3 program whose first trial randomized 388 participants across 72 sites in eight countries [11, 14]. Tesamorelin, a GHRH analog, was approved on 10 November 2010 on two pooled phase 3 trials of 806 patients, which reported a 15.4 percent treatment effect on visceral fat at week 26 [12, 15].
Teriparatide, a 34-residue fragment of parathyroid hormone, was approved under NDA 021318 on 26 November 2002 [13]. Each of these is a peptide prescribed by a licensed practitioner and dispensed by a pharmacy, and each carries labeling reviewed by the agency, the standard against which every other route is read [4].
Villegas Meza and colleagues reviewed injectable peptides in sports medicine from 2020 to 2025 and reported that GLP-1 receptor agonists were the only class supported by reproducible randomized evidence in the setting they examined, while regenerative peptides and secretagogues remained investigational [17]. The approved route is where the controlled human data live.
Section 503A opens compounding to three kinds of bulk substance
FDA’s bulks page states the statutory test: a 503A compounder may use a bulk substance that complies with a USP or NF monograph, or is a component of an FDA-approved drug, or appears on the 503A bulks list developed through rulemaking [1]. The substance must also come with a valid certificate of analysis from an establishment registered with FDA, and the preparation must follow a patient-specific prescription [1, 8].
For nominated substances that meet none of the three conditions yet, FDA’s interim policy sorts them into category 1, under evaluation and within an enforcement policy; category 2, significant safety risks identified; and category 3, nominated without adequate support [1]. The agency added in 2025 that substances nominated on or after 7 January 2025 are not placed into categories at all [1].
Compounded drugs are not FDA-approved, as the agency’s questions and answers page states, and FDA does not verify their safety, effectiveness or quality before marketing [4]. Gudeman and colleagues reviewed the framework in 2013 and reported that compounded drugs are exempt from good manufacturing practice regulations and that quality testing is inconsistent, which is why the certificate of analysis for each lot is the practice’s record [24].
The 2023 to 2026 category record changed the list of compoundable peptides
In September 2023 FDA placed BPC-157, TB-500, epitalon, MOTS-c, semax, KPV and several other peptides in category 2 [8]. On 22 April 2026 the nominators withdrew BPC-157, TB-500, CJC-1295, ipamorelin, injectable GHK-Cu and a dozen other substances, epitalon, KPV, MOTs-C and semax among them, and FDA moved them to a table of nominations withdrawn, where each sits in no interim category for that route [2]. Ipamorelin acetate appears in both tables because it remains in category 2 under the 503B interim policy [2].
GHK-Cu for non-injectable routes left category 1 with that withdrawal and returned on 14 May 2026 after one nominator retained its nomination for non-injectable routes, and FDA stated it intends to consult the advisory committee on the substance [3]. The Pharmacy Compounding Advisory Committee then reviewed seven peptides on 23 and 24 July 2026, with its votes constituting advice to the agency, which keeps the decision [6].
On 30 October 2026 HHS published a notice of availability for a draft interim enforcement discretion policy, 91 FR 68526, with comments open to 13 November 2026 [7]. The policy names six peptides, BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, and states that HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding them under 503A when ten conditions are met, among them a single active ingredient, a conforming certificate of analysis, MedWatch reporting and a patient-specific prescription [8]. A listed peptide stays in the withdrawn table and off the codified bulks list until rulemaking, and the policy describes itself as a draft not binding on HHS or the public [7, 8].
Investigational use under an IND is the third route
FDA’s IND page states that federal law requires an approved marketing application before a drug is shipped across state lines, and that the IND is the exemption through which a sponsor ships an investigational drug to clinical investigators [5]. A sponsor must wait 30 calendar days after submission before starting a trial, during which the agency reviews the IND for safety [5].
This is the route under which human evidence for unapproved peptides arrives. ClinicalTrials.gov held one BPC-157 record, a 2015 phase 1 study planned for 42 participants, until three studies were registered in 2026: a phase 2 trial planned for 120 participants, a phase 1 trial planned for 30, and a completed single-arm oral supplement study of 40 [26]. ExaVeyra offers BPC-157, TB-500 and other non-catalog peptides for IND-authorized clinical trials through our pharmacy partner, with the sponsor’s IND number, sponsor details and protocol confirmed before any supply.
Several questions remain open in the published record
The legal map is clearer than the evidence map. The points below set out what the public record does not yet settle for a practice reading it in November 2026.
- No rulemaking has placed any of the seven peptides reviewed in July 2026 on the 503A bulks list, and the advisory committee page posts no vote summary; the HHS policy document records that CDER recommended against listing each one while the committee voted in favor [6, 8].
- The HHS interim policy is a draft open for comment to 13 November 2026, establishes no rights and may be revisited if a safety signal or product quality issue arises [7, 8].
- Human efficacy evidence for most compounded peptides remains thin: the 2025 BPC-157 systematic review found 35 preclinical studies and one retrospective series of 12 patients [20], and Dominikowski and colleagues ranked GH-axis peptides from regulatory-grade trial data to a complete absence of human studies [18].
- Sermorelin’s position rests on its history as a component of a formerly approved drug, a question each pharmacy documents for its own board; Sigalos and Pastuszak reviewed the secretagogue class in 2018 and reported limited long-term outcome data [19].
- State board rules on compounding, office use and telehealth prescribing vary, and FDA’s questions and answers page assigns day-to-day oversight of 503A pharmacies to the state boards [4].
- Product quality outside a pharmacy is unverified: purity of 7.7 to 14.4 percent and endotoxin in every sample of online semaglutide, and arsenic and lead above parenteral limits in falsified peptides, were reported by independent laboratories [21, 22].
Research use only labeling carries no drug category of its own
The only FDA guidance that defines research use only labeling concerns in vitro diagnostic products in the laboratory research phase of development [10]. No equivalent category exists for a peptide vial, so the phrase describes a seller’s label and confers no legal status.
In a June 2023 warning letter the FDA stated that despite labeling for research purpose only and not for human consumption, a firm’s BPC-157 and TB-500 products were drugs intended for human use because of the claims made on its website and social media, and the agency listed them as unapproved new drugs [9]. The HHS interim policy of October 2026 states that one of its purposes is to discourage the widespread use of research-use-only peptides supplied by foreign manufacturers [8], and Mendias and Awan described that supply in 2026 as a gray market operating largely outside regulatory oversight [16].
The quality record explains the concern. Ashraf and colleagues made test purchases of semaglutide from six illegal online pharmacies in 2023 and reported that all three delivered vials were probable substandard or falsified products, with purity of 7.7 to 14.4 percent and endotoxin in every sample [21]. Janvier and colleagues analyzed the ten most frequently encountered falsified peptide products in Belgium and reported purity from 5 to 75 percent for cysteine-containing peptides and arsenic and lead at up to ten times the ICH parenteral limit [22].
State boards oversee the pharmacy and the prescriber
FDA’s questions and answers page states that state boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities, while FDA conducts surveillance and for-cause inspections [4]. A practice therefore reads two rulebooks: the federal 503A conditions and its own board’s rules on prescribing, dispensing and office use.
Shehab and colleagues reviewed 19 outbreaks linked to compounded sterile preparations between 2001 and 2013, with at least 1,000 cases including deaths, and reported that non-patient-specific compounding from nonsterile ingredients and repackaging of sterile products were the most common practices, with breaches in aseptic processing a consistent finding [23]. The patient-specific prescription at the heart of 503A, and the sterile compounding standards a board enforces, are the answer the record gives to that history.
Our 503A pharmacy partner holds nonresident licenses in 33 jurisdictions including Puerto Rico, and the catalog preparations are compounded by that partner against a patient-specific prescription. Where a controlled substance is prescribed, our 503A pharmacy partner dispenses it under its own DEA registration.
A table of routes open today and the documentation each one needs
The table sets out, for the peptides practices ask about most, which route is open as of 4 November 2026 and what a practice keeps on file. Status changes with each FDA and HHS update, so the date on this page is part of the answer.
| Peptide | Route open today (4 November 2026) | Documentation a practice needs | Source |
|---|---|---|---|
| Semaglutide, tesamorelin, teriparatide | FDA-approved drug products | A prescription; the approved labeling | [11, 12, 13] |
| Sermorelin, NAD+, glutathione, methylcobalamin | 503A, compounded by our pharmacy partner against a patient-specific prescription; glutathione, methylcobalamin and NAD sit in category 1 | Patient-specific prescription; the pharmacy’s record of the bulk substance basis and certificate of analysis | [1, 3] |
| GHK-Cu, topical | Category 1 for non-injectable routes since 14 May 2026; available as topical 503A preparations compounded to prescription | Patient-specific prescription; the route stated on the order | [3] |
| GHK-Cu, injectable | Nomination withdrawn April 2026; in no interim category | IND documentation for any investigational use | [2] |
| BPC-157, TB-500, epitalon, KPV, MOTS-c, semax | Withdrawn nominations; HHS draft interim policy names all six for 503A enforcement discretion under ten conditions; IND trials through our pharmacy partner | Sponsor’s IND number, sponsor details and protocol; for any 503A prescription, the pharmacy reads the ten conditions and route limits | [2, 7, 8] |
| CJC-1295, ipamorelin | Withdrawn 503A nominations, not on the HHS list; ipamorelin remains category 2 under 503B; IND trials through our pharmacy partner | Sponsor’s IND number, sponsor details and protocol | [2, 8] |
| Any peptide labeled research use only and sold for human use | No legal route; the FDA has treated such products as unapproved new drugs | None applies; the FDA stated the label does not change intended use | [9, 10] |
A documented peptide program begins with a verified account
Every route in the table runs through a licensed prescriber and a documented supply chain, and ExaVeyra supplies that chain to verified practices. Catalog peptides and hormone preparations are compounded by our 503A pharmacy partner against a patient-specific prescription, topical GHK-Cu is available as topical 503A preparations compounded to prescription, and non-catalog peptides are offered for IND-authorized clinical trials through our pharmacy partner with the sponsor’s IND number, sponsor details and protocol confirmed before any supply.
Anyone may apply or ask the scientific team a question without an NPI, and NPI verification, which takes 1 to 3 business days, gives access to the practitioner portal, product documentation and pricing. The rules moved several times between 2023 and 2026, and a practice that reads the dated record alongside its supplier is well placed for whatever the next rulemaking decides.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Content current as of 05/14/2026; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-actAgency compounding page (CDER). Carries in this article: the three routes by which a 503A compounder may use a bulk substance (USP or NF monograph, component of an FDA-approved drug, or the 503A bulks list set by rulemaking), the requirement for a valid certificate of analysis from an FDA-registered establishment, the definitions of categories 1, 2 and 3, and the statement that substances nominated on or after 7 January 2025 are not placed into categories.
- 2.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 of the interim policies, with the table of substances nominated but withdrawn). Content current as of 04/22/2026; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risksAgency compounding page (CDER). Carries in this article: BPC-157, CJC-1295, GHK-Cu for injectable routes, thymosin beta-4 fragment (TB-500), epitalon, MOTS-c, semax, KPV and others sit in the table of substances previously in category 2 whose nominations were withdrawn in April 2026; ipamorelin acetate appears in both tables because it remains in category 2 under the 503B interim policy; ibutamoren and kisspeptin-10 remain in category 2.
- 3.U.S. Food and Drug Administration. 503A Bulk Drug Substances Categories: Category 1 (Bulk Drug Substances Under Evaluation) and Category 3 (Nominated Without Adequate Support). PDF updated May 14, 2026; downloaded and verified 4 November 2026. https://www.fda.gov/media/94155/downloadAgency list document (CDER). Carries in this article: GHK-Cu (except for injectable routes of administration) was removed from category 1 on 22 April 2026 when nominations were withdrawn and added back on 14 May 2026 after one nominator retained its nomination for non-injectable routes; glutathione, methylcobalamin and nicotinamide adenine dinucleotide also appear in category 1 on that date.
- 4.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Content current as of 09/16/2025; verified 4 November 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answersAgency explainer page (CDER). Carries in this article: compounded drugs are not FDA-approved, so the agency does not verify their safety, effectiveness or quality before marketing, and state boards of pharmacy generally have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not outsourcing facilities.
- 5.U.S. Food and Drug Administration. Investigational New Drug (IND) Application. Content current as of 09/16/2026; verified 4 November 2026. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-applicationAgency explainer page (CDER). Carries in this article: federal law requires an approved marketing application before a drug is shipped across state lines, the IND is the exemption that lets a sponsor ship an investigational drug to investigators, and a sponsor must wait 30 calendar days after submission before starting a trial; the regulation is 21 CFR part 312, read on govinfo.gov the same day.
- 6.U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda, briefing documents and FDA presentations). Content current as of 08/06/2026; verified 4 November 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026Agency advisory committee page. Carries in this article: the committee discussed BPC-157, KPV, TB-500 and MOTS-c on 23 July 2026 and emideltide (DSIP), semax and epitalon on 24 July 2026 for possible inclusion on the 503A bulks list, with the use FDA evaluated stated for each; the page posts no vote summary or minutes as read on 4 November 2026.
- 7.U.S. Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. Federal Register. 2026;91:68526-68527 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496), published 30 October 2026, comments to 13 November 2026; verified 4 November 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substancesFederal Register notice of availability of a draft interim policy. Carries in this article: HHS stated it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding under 503A with a peptide listed in the policy appendix while rulemaking proceeds, that the draft establishes no rights and is not binding, and that FDA rulemaking may later propose adding some or all of those peptides to the 503A bulks list.
- 8.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (interim access list) and Appendix B (identities, route limits and testing standard). 16 pages; read on hhs.gov 4 November 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdfDraft interim policy document. Carries in this article: Appendix A lists BPC-157, epitalon, KPV, MOTS-c, semax and TB-500; the ten conditions (registered original manufacturer with a conforming certificate of analysis, single active ingredient, MedWatch and state reporting, the not-for-resale label statement, a 510(k)-cleared syringe as the only device, oral bioavailability documentation for oral forms, a patient-specific prescription and compliance with the rest of the Act); the route limits per peptide; the statement that the policy aims to discourage research-use-only peptides from foreign manufacturers; and the record that CDER recommended against listing each peptide while the advisory committee voted in favor.
- 9.U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning Letter to Warrior Labz SARMS (reference 655280), issued 12 June 2023, posted 20 June 2023; verified 4 November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023Agency enforcement letter. Carries in this article: the agency stated that despite labeling for research purpose only and not for human consumption, the firm’s products, BPC-157 and TB-500 among them, were drugs intended for human use because of the claims made for them, and listed them as unapproved new drugs under the Act.
- 10.U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and FDA Staff. Content current as of 02/20/2018; verified 4 November 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-onlyAgency guidance page (CDRH and CBER). Carries in this article: the only FDA guidance that defines research use only labeling concerns in vitro diagnostic products in the laboratory research phase of development, which is why the phrase carries no drug category of its own.
- 11.U.S. Food and Drug Administration, Drugs@FDA. NDA 209637, Ozempic (semaglutide) injection; original approval 12/05/2017. Record verified 4 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637Agency approval database record (CDER). Carries in this article: the approval date of a peptide drug marketed under a new drug application, the first of the three legal routes. The product name is a trademark of its owner and is named only to identify the record.
- 12.U.S. Food and Drug Administration, Drugs@FDA. BLA 022505, Egrifta (tesamorelin for injection); original approval 11/10/2010. Record verified 4 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505Agency approval database record (CDER). Carries in this article: the approval date of a GHRH analog peptide, the example that a secretagogue class can hold an approved member while its unapproved relatives sit in category 2. The product name is a trademark of its owner.
- 13.U.S. Food and Drug Administration, Drugs@FDA. NDA 021318, Forteo (teriparatide) injection; original approval 11/26/2002. Record verified 4 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021318Agency approval database record (CDER). Carries in this article: the approval date of a 34-residue peptide fragment drug, an example that peptide fragments reach approval through the same application route as any drug. The product name is a trademark of its owner.
- 14.Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. PMID 28110911. doi:10.1016/S2213-8587(17)30013-XDouble-blind randomized placebo-controlled phase 3a trial at 72 sites in eight countries; 388 participants randomized, 30 weeks. Carries in this article: the size and design of a pivotal trial behind an approved peptide, with HbA1c the primary endpoint, as the standard against which unapproved peptide evidence is read. Funding: the manufacturer.
- 15.Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713. doi:10.1210/jc.2010-0490Pooled analysis of two multicenter double-blind placebo-controlled phase 3 trials; 806 patients randomized 2:1, 26 weeks plus a 26-week extension. Carries in this article: the trial reported a 15.4 percent treatment effect on visceral adipose tissue by computed tomography at week 26, the scale of evidence behind the approved GHRH analog. Funding: the manufacturer.
- 16.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID 41966639. doi:10.1007/s40279-026-02437-0Narrative review of approved and unapproved peptides marketed direct to patients. Carries in this article: the authors describe a parallel gray market of unapproved compounds operating largely outside regulatory oversight, with favorable animal data and scarce human safety data. Disclosure: one author reports unrelated consulting fees.
- 17.Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026;14(5). PMID 42160466. doi:10.2106/JBJS.RVW.26.00027Structured narrative review of human and translational studies from January 2020 to August 2025. Carries in this article: GLP-1 receptor agonists were the only class with reproducible randomized evidence in the musculoskeletal setting reviewed, while regenerative peptides and secretagogues remained investigational with product quality concerns and antidoping restrictions. Funding: a research institute listed in the record.
- 18.Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PMID 42395176. doi:10.3389/fendo.2026.1822475Narrative review contrasting peer-reviewed pharmacology with online self-administration protocols for GHRH analogs, secretagogues and GH fragments. Carries in this article: these agents are marketed as research compounds, and the authors stratify them from regulatory-grade trial data to a complete absence of human studies. Disclosure: the authors declare no commercial relationships.
- 19.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID 28400207. doi:10.1016/j.sxmr.2017.02.004Narrative review of clinical studies of GH secretagogues in human subjects. Carries in this article: the physiological description of secretagogues as agents that promote pulsatile GH release subject to feedback, the class in which sermorelin, CJC-1295 and ipamorelin are discussed. Funding: NIH training support listed in the record; no conflicts reported.
- 20.Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949. doi:10.1177/15563316251355551Systematic review to June 2024; 36 studies, 35 preclinical and 1 clinical. Carries in this article: the example of a widely sold peptide whose human evidence is a single retrospective series of 12 patients, the gap between the 503A paperwork question and the evidence question. Disclosure: several authors declare industry relationships.
- 21.Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024;26:e65440. PMID 39509151. doi:10.2196/65440Market surveillance of 1,080 search links plus test purchases from six illegal online pharmacies with laboratory analysis. Carries in this article: 134 links led to 59 illegal pharmacy sites, all three delivered vials were probable substandard or falsified products, semaglutide purity measured 7.7 to 14.4 percent, and endotoxin was detected in every sample. Disclosure: two authors are employees of a research company named in the record.
- 22.Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PMID 30029448. doi:10.1016/j.talanta.2018.06.023Laboratory analysis of the ten most frequently encountered falsified peptide products from three suspected illegal internet pharmacies. Carries in this article: high variation in content per unit, purity between 5 and 75 percent for cysteine-containing peptides, and arsenic and lead at up to ten times the ICH parenteral limit. Disclosure: public health institute authors.
- 23.Shehab N, Brown MN, Kallen AJ, Perz JF. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned. J Patient Saf. 2018;14(3):164-173. PMID 26001553. doi:10.1097/PTS.0000000000000188Review of CDC reports, FDA communications and published literature; 19 outbreaks linked to pharmacy-compounded sterile preparations with at least 1,000 cases including deaths. Carries in this article: non-patient-specific compounding from nonsterile ingredients and repackaging were the most common practices, with breaches in aseptic processing a consistent finding, the reason the patient-specific prescription and sterile compounding standards sit at the center of 503A. Funding: CDC intramural.
- 24.Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. PMID 23526368. doi:10.1007/s40268-013-0005-9Narrative review of compounding oversight and quality. Carries in this article: compounded drugs are exempt from good manufacturing practice regulations and quality testing is inconsistent, the structural reason an approved product and a compounded preparation are documented differently. Disclosure: authors employed by a pharmaceutical manufacturer.
- 25.World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard, in force 1 January 2026 (S0 Non-approved substances; S2.2.4 Growth hormone releasing factors; S2.3 Growth factors and growth factor modulators). PDF read on wada-ama.org, verified 4 November 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdfInternational standard, English text. Carries in this article: legality under US drug law and status in sport are separate questions; S0 names BPC-157, S2.2.4 names CJC-1295, sermorelin, tesamorelin, ipamorelin and the GHRPs, and S2.3 names thymosin-beta-4 derivatives including TB-500, all prohibited at all times.
- 26.ClinicalTrials.gov. Registered studies returned for the term BPC-157 on 5 November 2026: NCT02637284 (phase 1, 42 participants estimated, started 2015, status unknown); NCT07437547 (phase 2, 120 participants estimated, recruiting, started February 2026); NCT07803250 (phase 1, 30 participants estimated, not yet recruiting, estimated start January 2027); NCT07752381 (single-arm oral supplement study, 40 participants, completed, first posted 7 August 2026). https://clinicaltrials.gov/search?term=BPC-157Registry records read through the v2 API. Carries in this article: the investigational route in practice, with three studies of an unapproved peptide registered in 2026 after a decade with a single record, the way human evidence and an IND-based supply chain arrive together.